Protocolo de Actuación en Mieloma múltiple - Sociedad Asturiana ...

16. Kumar SK et al. Blood 2008;111:2516–2520
17. Kumar SK eta. Risk of progression and survival in multiple myeloma relapsing after therapy
with IMIDs and Bortezomib: a multicenter international myeloma working group study.
Leukemia 2012; 26: 149-57
18. Lacy M et al. Pomalidomide plus low-dose dexametasone in myeloma refractory to both
Bortezomib and lenalidome: comparison of dosisng strategies in dual-refractory disease.
Blood 2011; 118: 2970-75
19. Lazzarino M et al. DCEP is an effective regimen for peripheral blood stem cell collection in
multiple myeloma. BMT 2001; 28: 935-939
20. Lentzsch,S O'Sullivan A, Kennedy R et al. Combination of Bendamustine, Lenalidomide, and
Dexamethasone In Patients with Refractory or Relapsed Multiple Myeloma Is Safe and Highly
Effective: Results of a Phase I Clinical Trial
Blood 2010; 116: abst. 989.
21. Lonial S, Jakubowiak A, Jagannath R et al , A Phase 2 Study of Elotuzumab in Combination
with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory
Multiple Myeloma. Blood 2011; 118: abst. 303.
22. Ludwig H, Kasparu H, Linkesch W et al, Bortezomib-Bendamustine-Dexamethasone in
Patients with Relapsed/Refractory Multiple Myeloma (MM) Shows Marked Efficacy and Is
Well Tolerated, but Assessment of PNP Symptoms Shows Significant Discrepancies Between
Patients and Physicians. Blood 2011; 118: abst.2928.
23. Madan S, Lacy M, Dispenzieri A et al. Efficacy of retreatment with IMIDs in patients
receiving IMIDs for initial therapy of newly diagnosed multiple myeloma. Blood 2011; 116:
1763-1765
24. Mansi H, Cunninghan D, Viner C et al. Repeat administration of high dose melphalan in
relapsed myeloma. Br J Cancer 1993; 88: 983-7
25. Mateos MV et al. VMP compared MP in previously untreated multiple myeloma: updated
follow-up and impact of subsequent therapy in the phase III VISTA trial J Clin Oncol 2010;
28:2259-2266
26. Mikhael JR, Zadeh S, Stewart AK et al. Second autologous stem cell transplant as salvage
therapy in patients with relapsed multiple myeloma. Blood 2009; 114; abst. 3418
27. Orlowski RZ, Nagler A, Sonneveld P et al. Randomized phase III study of pegylated
liposomal doxorubicin plus Bortezomib compared with Bortezomib alone in relapsed or
refractory multiple myeloma: combination therapy improves time to progression. J Clin
Oncol. 2007;25: 3892-901.
28. Palumbo A, Gay F, Bringhen S et al. Bortezomib, doxorrucin and dexametasone in advanced
multiple myeloma. Ann Oncol 2008; 19: 1160-5
29. Palumbo A and Anderson K. Multiple Myeloma. N Engl J Med 2011; 364: 1046-60
30. Petrucci T, Blau J, Corradini P et al. Efficacy and safety of retreatment with Bortezomib in
patients with multiple myeloma: Interim results from RETRIEVE, a prospective International
phase 2 Study. Haematologica 2010; 95(s2):152
Grupo Asturiano de Linfoma y Mieloma
70